Finnair’s Q3 results came in clearly above estimates as strong development in unit revenues drove to...
Consti reported Q3 figures that were in line with our estimates.
Verkkokauppa.com’s Q3 result came in soft as expected.
CapMan continued its good performance in Q3 and results apart from carried interest corresponded to ...
Redeye endorses aXichem’s new patent for phenylcapsaicin for use in the treatment of idiopathic pulm...
Redeye takes a more positive stance towards Addnode following an excellent Q3 report, driven by stro...
Redeye reiterates its SEK 132 base case for BONESUPPORT following the Q3 report.
Redeye comments on Sleep Cycle's Q3 report, which showed higher profitability than expected, while t...
Redeye states that the Q3 report was better than expected on EBITDA and in line with net sales estim...
Redeye remains positive on the investment case in Xbrane Biopharma following its Q3 2022 report.
Redeye is impressed by the better-than-expected Q3 report this morning.
Redeye states that the Q3 report was strong. Investment Management once again exceeded Redeye’s esti...
Redeye updates its estimates on Starbreeze. Due to the strong dollar exposure, and relatively high p...
Redeye provides a preview ahead of Embracer Group’s Q2 2022/23 report, due on 17th November.
Redeye lowers the estimates as we see a continued challenging market into 2023.
On 27 October 2022, Vow released its Q3 update (the company reports semi-annually), posting nearly d...
Serneke delivered a mixed set of numbers, with Q3 sales of SEK 2.
Q3 sales grew 26% organically, +2% vs cons Guides for strong Q4 & H1 2023 from ATH order book Consen...
EBITA SEK 214m (-8% vs. cons. 232m) Consensus ’23e-’24e EBITA likely down by ~1-2% Trading at 11x ’2...
EPS and EBITDA 29% and 27% below ABGSCe Joinery and Pellets better than expected Strong cash flow re...
